A specialised portfolio of advanced antiretroviral medications utilised in the clinical management and suppression of Human Immunodeficiency Virus (HIV).
Human Immunodeficiency Virus (HIV) is a virus that attacks the immune system, specifically the CD4 + T-lymphocytes that help protect the body from infections. Over time, reduced CD4 counts can make everyday illnesses more severe and increase the risk of opportunistic infections.
In Hong Kong, HIV is managed primarily through a lifelong regimen of antiretroviral medicines. These medicines work by interrupting the virus’s ability to replicate, keeping the viral load low and preserving immune function.
The category of HIV medications includes agents such as Abacavir, Dolutegravir, and Tenofovir Disoproxil, among others. They are typically taken daily in tablet or capsule form, and many are combined into a single pill to simplify daily routines.
Patients often start HIV medicines soon after diagnosis and continue them for the rest of life, allowing most individuals to lead active, healthy lives while reducing the chance of onward transmission.
HIV medicines are used to control the infection itself, aiming to keep the viral load undetectable and CD4 counts within a healthy range. By doing so, they help prevent a range of HIV-related conditions, including:
Secondary conditions that may arise in people living with HIV, such as chronic kidney disease or lipid abnormalities, are also monitored while on therapy, as some medicines can influence these health aspects.
Overall, effective use of HIV medicines lessens the impact of the virus on daily activities, work, and social life.
Each category shares some drug classes with HIV therapy but serves distinct preventive or co-infection purposes.
These drugs block an early step of viral replication.
INSTIs prevent the virus from inserting its genetic material into host cells.
NNRTIs bind to a different site on the reverse transcriptase enzyme, halting replication.
Protease inhibitors stop the virus from maturing into an infectious form.
Many patients receive two or more active agents combined in one tablet to reduce pill burden.
The choice of a specific regimen depends on individual health profiles, virus characteristics, and potential drug interactions.
Antiretroviral therapy (ART) is the standard approach for controlling HIV. It works by consistently suppressing viral replication, which allows the immune system to recover and maintain function.
For most patients, ART is a lifelong commitment, but the regimen can be adjusted over time if resistance develops or if side-effect profiles change. Modern formulations are designed for once-daily dosing, supporting adherence.
While ART greatly reduces the chance of transmitting HIV to others, it does not eradicate the virus; instead, it keeps the virus at levels that are undetectable by standard laboratory testing.
Understanding the basic principles of viral load monitoring, CD4 count trends, and the role of drug resistance helps patients stay informed about their health journey.
These groups share the common goal of maintaining immune health and minimizing virus-related complications.
Antiretroviral therapy (ART): The combination of medicines used to treat HIV infection.
Viral load: The amount of HIV genetic material measured in the blood, indicating how actively the virus is replicating.
CD4 count: A laboratory measurement of immune cells targeted by HIV; higher counts reflect stronger immune function.
Drug resistance: The ability of HIV to continue replicating despite the presence of medicines, often caused by viral mutations.
Fixed-dose combination: A single tablet that contains two or more antiretroviral agents, simplifying dosing.
HIV is a virus that primarily infects CD4 + T-lymphocytes, weakening the immune system over time. Reduced immune function can make ordinary infections more serious and increase susceptibility to specific illnesses.
Consistent daily dosing maintains drug levels that suppress viral replication, keeping the viral load low and allowing the immune system to recover. Gaps in dosing can give the virus an opportunity to multiply and potentially develop resistance.
Yes, if the virus is exposed to insufficient drug concentrations, it may acquire mutations that reduce the effectiveness of a given medicine. Monitoring viral load helps identify resistance early.
Integrase inhibitors stop the viral enzyme that inserts HIV DNA into the host cell’s genome, targeting a later stage of the replication cycle compared to reverse transcriptase inhibitors.
Many modern regimens combine two or three active agents into a single tablet, known as a fixed-dose combination, to reduce pill burden and support adherence.
Success is commonly evaluated by an undetectable viral load (typically fewer than 20-50 copies per milliliter) and a stable or rising CD4 count.
Regular viral load tests track how well the medicines are controlling the virus, guiding clinicians on whether a regimen remains effective.
Maintaining a balanced diet, regular exercise, and avoiding smoking or excessive alcohol can support overall health and complement the effects of antiretroviral therapy.
Pregnant patients receive antiretroviral regimens that are safe for both mother and fetus, aiming to keep viral load undetectable and reduce the chance of mother-to-child transmission.
Fixed-dose combinations simplify treatment by reducing the number of pills required each day, which can improve adherence and overall treatment outcomes.
